文 献 9）Setoyama D, Yoshino A, Takamura M, Okada G, Iwata M, Tsunetomi K, et al. Personality classification enhances blood metabolome analysis and biotyping for major depressive disorders: two-species investigation. J Affect Disord 2021; 279: 20-30. 10）Sakurai H, Setoyama D, Kato TA, Tachimori H, Murao M, Matsumoto Y, et al. Acute and long-term effects of repeated ketamine infusions in treatment-resistant depression and associated metabolite changes. Psychiatry Clin Neurosci 2025; 79: 645-5211）Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013; 74: 250-6.12）Ionescu DF, Bentley KH, Eikermann M, Taylor N, Akeju O, Swee MB, et al. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. J Affect Disord 2019; 243: 516-24. 13）Li W, Zhou Y, Liu W, Wang C, Lan X, Zhang Z, et al. Long-term outcomes of repeated ketamine infusions in patients with unipolar and bipolar depression: A naturalistic follow-up study. J Affect Disord 2022; 300: 172-8.14）Krivosova M, Gondas E, Murin R, Dohal M, Ondrejka I, Tonhajzerova I, et al. The plasma levels of 3-hydroxybutyrate, dityrosine, and other markers of oxidative stress and energy metabolism in major depressive disorder. Diagnostics 2022; 12: 813.15）Saito N, Itoga M, Minakawa S, Kayaba H. Serum 3-hydroxybutyrate in patients with psychogenic somatoform symptoms may be a predictor of the effectiveness of sertraline and venlafaxine. Int J Gen Med 2021; 14: 1785-95.218 1）Friedrich MJ. Depression is the leading cause of disability around the world. JAMA 2017; 317: 1517. 2）Sakurai H, Noma H, Watanabe K, Uchida H, Furukawa TA. Cumulative remission rate after sequential treatments in depression: reappraisal of the STAR*D trial data. World Psychiatry 2024; 23: 156-7. 3）Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry 2018; 25: 1592-1603. 4）Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Curr Med Res Opin 2017; 33: 701-11. 5）Sakurai H, Jain F, Foster S, Pedrelli P, Mischoulon D, Fava M, et al. Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review. J Affect Disord 2020; 276: 660-6. 6）Alnefeesi Y, Chen-Li D, Krane E, Jawad MY, Rodrigues NB, Ceban F, et al. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. J Psychiatr Res 2022; 151: 693-709. 7）Sakurai H, Hoeppner B, Jain F, Foster S, Pedrelli P, Mischoulon D, et al. Use of Staging Models for Treatment-Resistant Depression Is Not Helpful in Predicting Nonresponse to Acute Intravenous Ketamine Treatment. J Clin Psychopharmacol 2022; 42: 140-5. 8）Setoyama D, Kato TA, Hashimoto R, Kunugi H, Hattori K, Hayakawa K, et al. Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients-A multicenter pilot analysis. PLoS One 2016; 11: e0165267.
元のページ ../index.html#236